2 Information about lenvatinib and sorafenib
Marketing authorisation indications
Lenvatinib (Lenvima, Eisai)
Adults with 'progressive, locally advanced or metastatic differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine'.
Sorafenib (Nexavar, Bayer)
Adults with 'progressive, locally advanced or metastatic differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine'.
Dosage in the marketing authorisations
Lenvatinib (Lenvima, Eisai)
24 mg (2×10 mg capsules and 1×4 mg capsule) once daily.
Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.
Sorafenib (Nexavar, Bayer)
400 mg (2×200 mg tablets) twice daily (equivalent to a total daily dose of 800 mg).
Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.
Prices
Lenvatinib (Lenvima, Eisai)
The list price of Lenvatinib is £1,437 per 30×10 mg pack and per 30×4 mg pack (excluding VAT; BNF online [accessed July 2017]).
Sorafenib (Nexavar, Bayer)
The list price of sorafenib is £3,576.56 per 112×200 mg pack (excluding VAT; BNF online [accessed July 2017]).